RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 24 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 24

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Hospital of Guilin Medical University桂林医学院附属医院GuilinHospital page
  2. Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
  3. Study siteFirst Affiliated Hospital of Xiamen University厦门大学附属第一医院XiamenHospital page
  4. Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
  5. Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
  6. Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
  7. Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
  8. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  9. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  10. Study siteJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page
  11. Study siteJiangxi Cancer Hospital江西省肿瘤医院NanchangHospital page
  12. Study siteJilin Cancer Hospital吉林省肿瘤医院ChangchunHospital page
  13. Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
  14. Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
  15. Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
  16. Study siteShengjing Hospital of China Medical University中国医科大学附属盛京医院ShenyangHospital page
  17. Study siteSichuan Cancer Hospital四川省肿瘤医院ChengduHospital page
  18. Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
  19. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
  20. Study siteWest China Hospital四川大学华西医院ChengduHospital page
  21. Study siteXiangyang Central Hospital襄阳市中心医院XiangyangHospital page
  22. Study siteXinqiao Hospital, Army Medical University陆军军医大学第二附属医院(新桥医院)ChongqingHospital page
  23. Study siteYunnan Cancer Hospital云南省肿瘤医院KunmingHospital page
  24. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07622186, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Participants must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC).

    Inclusion criterion 2

  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

    Inclusion criterion 4

  4. Participants with other malignant tumors within 3 years before the first dose of study treatment.

    Exclusion criterion 1

  5. Pregnant or breastfeeding women.

    Exclusion criterion 12

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07622186, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Male or female, age ≥ 18 years and ≤ 75 years at the time of signing the informed consent form (ICF).
  • Participants must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC).
  • At least one measurable lesion as assessed by the investigator according to RECIST v1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Life expectancy ≥ 12 weeks as assessed by the investigator.
  • Adequate organ and bone marrow function.
  • Male and female participants must agree to use highly effective methods of contraception during the study treatment period.
  • Participants must voluntarily join this study, sign the ICF, and be able to comply with the visits and related procedures specified in the protocol.

Exclusion Criteria:

  • Participants with other malignant tumors within 3 years before the first dose of study treatment.
  • Active or untreated central nervous system (CNS) metastasis.
  • Current uncontrolled concomitant diseases
  • Clinically severe lung damage due to complications of lung disorder
  • Participants with a history of interstitial lung disease (ILD)/non-infectious pneumonitis
  • A history of severe skin diseases
  • Unresolved toxicity from prior anti-tumor therapy
  • Serious infection within 4 weeks before the first dose of study treatment
  • Known active pulmonary tuberculosis.
  • Participants who have undergone major surgery or had severe trauma within 4 weeks before the first dose, or are expected to require major surgery during the study.
  • Known history of allogeneic organ transplant or allogeneic hematopoietic stem cell transplant.
  • Pregnant or breastfeeding women.
  • Other conditions deemed by the investigator as unsuitable for participation in this clinical trial.

Quoted from ClinicalTrials.gov, NCT07622186, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07622186, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07622186